Abstract
Antiplatelet therapy plays an important role in the treatment of patients suffering from acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI) in order to prevent atherothrombotic events and restenosis or ischemic reocclusion, respectively. Moreover, stent implantation is often performed along with PCI to ensure that the arteries remain open. However, stent thrombosis ST is a possible complication which can occur up to about one year after the procedure. Therefore, it is standard to treat patients with a dual antiplatelet regime whereby aspirin is combined with either clopidogrel, prasugrel or ticagrelor. This review summarizes the characteristics of these P2Y12 antagonists and evaluates the current and future clinical guidelines for antiplatelet therapy in the setting of PCI with or without stenting.
Keywords: Clopidogrel, drug-eluting stent, prasugre, stent thrombosis, ticagrelor.
Cardiovascular & Hematological Disorders-Drug Targets
Title:Recent Developments in Antiplatelet Therapy after Percutaneus Coronary Intervention
Volume: 14 Issue: 3
Author(s): Mustafa Yildiz, Banu Sahin Yildiz, Mustafa Ozan Gursoy and Ibrahim Akin
Affiliation:
Keywords: Clopidogrel, drug-eluting stent, prasugre, stent thrombosis, ticagrelor.
Abstract: Antiplatelet therapy plays an important role in the treatment of patients suffering from acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI) in order to prevent atherothrombotic events and restenosis or ischemic reocclusion, respectively. Moreover, stent implantation is often performed along with PCI to ensure that the arteries remain open. However, stent thrombosis ST is a possible complication which can occur up to about one year after the procedure. Therefore, it is standard to treat patients with a dual antiplatelet regime whereby aspirin is combined with either clopidogrel, prasugrel or ticagrelor. This review summarizes the characteristics of these P2Y12 antagonists and evaluates the current and future clinical guidelines for antiplatelet therapy in the setting of PCI with or without stenting.
Export Options
About this article
Cite this article as:
Yildiz Mustafa, Yildiz Sahin Banu, Gursoy Ozan Mustafa and Akin Ibrahim, Recent Developments in Antiplatelet Therapy after Percutaneus Coronary Intervention, Cardiovascular & Hematological Disorders-Drug Targets 2014; 14 (3) . https://dx.doi.org/10.2174/1871529X14666140823142031
DOI https://dx.doi.org/10.2174/1871529X14666140823142031 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Collateral Circulation in Chronic Total Occlusions – an interventional perspective
Current Cardiology Reviews Targets for Anti-T. cruzi Drugs in the Post-Genomic Era
Current Enzyme Inhibition Different Effects of Thiazolidinediones on Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus: Pioglitazone vs Rosiglitazone
Current Drug Safety Influences of Maternal Nutritional Status on Vascular Function in the Offspring
Current Drug Targets Glucagon Like Peptide-1 and Atherosclerosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Cholesterol Ester Transfer Protein (CETP), Postprandial Lipemia and Hypolipidemic Drugs
Current Medicinal Chemistry Chest Pain, Panic Disorder and Coronary Artery Disease: A Systematic Review
CNS & Neurological Disorders - Drug Targets Relationship Between the Pharmacokinetics of Levosimendan and Its Effects on Cardiovascular System
Current Drug Metabolism Type 2 Diabetes and Heart Failure: Challenges and Solutions
Current Cardiology Reviews Anti-Inflammatory Therapy in Uveitis
Recent Patents on Inflammation & Allergy Drug Discovery Relationships of Birthweight and Postnatal Growth with Metabolic Risk Factors in Junior School Children in Korea
Current Hypertension Reviews Editorial: Liraglutide and Cardiometabolic Effects: More than Just Another Antiobesity Drug?
Current Vascular Pharmacology Cathelicidins: Peptides with Antimicrobial, Immunomodulatory, Anti- Inflammatory, Angiogenic, Anticancer and Procancer Activities
Current Protein & Peptide Science Adequacy of Quality Assurance Programs for a Corn Meal Production Unit
The Natural Products Journal Targeting Myocardial Metabolism for the Treatment of Stable Angina
Current Pharmaceutical Design Management of Peyronie's Disease after Collagenase (Xiaflex:<sup>®</sup>)
Current Drug Targets Nanotechnological Strategies for the Treatment of Neglected Diseases
Current Pharmaceutical Design Pharmacological Activity of Cardiovascular Agents from Herbal Medicine
Cardiovascular & Hematological Agents in Medicinal Chemistry Nocturnal Hypertension, Nondipping Phenomenon and Target Organ Damage in Obstructive Sleep Apnea Patients - The Bad and the Worse
Current Respiratory Medicine Reviews Coronary CT and the Coronary Calcium Score, the Future of ED Risk Stratification?
Current Cardiology Reviews